OR WAIT null SECS
October 20, 2025
Article
A total of 8 acute and chronic disease factors, including hypertension, obesity, and physical inactivity, compound to increase mortality and CVD risk.
Rybelsus marks the first oral GLP-1 for major adverse cardiovascular events in adult patients with T2D, opening a new cardiovascular treatment pathway.
CHEST 2025 data suggest OSA is an "effect modifier" on the mortality benefit of GLP-1 receptor agonists in patients co-diagnosed with type 2 diabetes.
October 14, 2025
New research links sleep-related leg movements to a higher risk of diabetes.
Podcast
This episode covers the upcoming glucose monitor Biolinq Shine, the Insulin Icodec FDA resubmission, and the end of Eli Lilly's work in T2D.
Celebrate 150 episodes of Diabetes Dialogue as hosts reflect on advancements in diabetes technology and impactful discussions in patient care.
October 08, 2025
The Q3 recap for endocrinology spotlights major FDA decisions, new guidelines for managing diabetes during pregnancy, and major clinical trial updates.
October 07, 2025
Catch up on FDA decisions, critical trial results, and expert perspectives on endocrinology.
October 02, 2025
This episode highlights the recent technological advancements made by Medtronic Diabetes in treating type 1 and 2 diabetes.
September 29, 2025
The resubmission is based on results from 5 randomized clinical trials in the ONWARDS type 2 diabetes phase 3a program.
